CHRONIC MYELOMONOCYTIC LEUKEMIA
Clinical trials for CHRONIC MYELOMONOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new CHRONIC MYELOMONOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo for tough leukemias hits roadblock: trial ends early
Disease control TerminatedThis study tested a combination of two drugs, venetoclax and decitabine, in 235 people with certain blood cancers (like acute myeloid leukemia and high-risk myelodysplastic syndrome) that either came back or didn't respond to prior treatment, or in older adults who couldn't handl…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:31 UTC
-
New combo therapy tested for hard-to-treat blood cancers
Disease control TerminatedThis early-phase study tested a new drug called DSP107 combined with standard chemotherapy drugs (azacitidine with or without venetoclax) in people with relapsed or refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML).…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Kahr Medical • Aim: Disease control
Last updated May 17, 2026 03:28 UTC
-
Promising combo for tough blood cancer hits snag: trial halted
Disease control TerminatedThis study tested two drugs, venetoclax and azacitidine, together in people with a serious type of bone marrow cancer called high-risk myelodysplastic syndrome (MDS). The goal was to find the best dose and see if the combo could shrink or control the cancer. The trial included 51…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:02 UTC